@article{d957002a0012487da9025ab31f3796a2,
title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy",
abstract = "Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.",
author = "Goetz, {Matthew P.} and Katrin Sangkuhl and Guchelaar, {Henk Jan} and Matthias Schwab and Michael Province and Michelle Whirl-Carrillo and Symmans, {W. Fraser} and McLeod, {Howard L.} and Ratain, {Mark J.} and Hitoshi Zembutsu and Andrea Gaedigk and {van Schaik}, {Ron H.} and Ingle, {James N.} and Caudle, {Kelly E.} and Klein, {Teri E.}",
note = "Funding Information: This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264), PharmGKB (R24GM61374), and PharmVar (R24 GM123930). M.S. is supported by grants of the German Federal Ministry of Education and Research (BMBF 01ZP0502 and 01EK1509A), the EU H2020 UPGx grant (668353) and the Robert Bosch Foundation, Stuttgart, Germany. Supported in part by Specialized Programs of Research Excellence Grants No. P50CA 116201 (M.P.G., J.N.I.). We acknowledge the critical input of Dr. M. Relling and members of the Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network, funded by the National Institutes of Health. CPIC is a registered service mark of the U.S. Department of Health & Human Services (HHS). Funding Information: We acknowledge the critical input of Dr. M. Relling and members of the Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network, funded by the National Institutes of Health. CPIC is a registered service mark of the U.S. Department of Health & Human Services (HHS). Funding Information: This work was funded by the National Institutes of Health (NIH) for CPIC (R24GM115264), PharmGKB (R24GM61374), and PharmVar (R24 GM123930). M.S. is supported by grants of the German Federal Ministry of Education and Research (BMBF 01ZP0502 and 01EK1509A), the EU H2020 UPGx grant (668353) and the Robert Bosch Foundation, Stuttgart, Germany. Supported in part by Specialized Programs of Research Excellence Grants No. P50CA 116201 (M.P.G., J.N.I.). Publisher Copyright: {\textcopyright} 2018 American Society for Clinical Pharmacology and Therapeutics",
year = "2018",
month = may,
doi = "10.1002/cpt.1007",
language = "English",
volume = "103",
pages = "770--777",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
number = "5",
}